Full-Time
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Senior
Marcy-l'Étoile, France
- 5 to 8 years' experience
- Experience developing deployable code and deploying models in product-focused development under an agile environment
- Experience in production-ready software development
- Track record of applying machine learning/deep learning approaches to solve various problems (commercial, industrial, research)
- Experience with database mining, big data, and large-scale virtual screening
- Experience in a healthcare company is a strong plus
- Experience in IoT and timeseries forecasting is a plus
- Excellent written and verbal communication skills
- Experience working with multiple teams to drive alignment and results
- Service-oriented, flexible, positive team player
- Self-motivated, takes initiative
- Problem solving & critical thinking
- Expertise in business analysis, data visualization and data storytelling
- Expertise with core data science languages (such as Python, R), and familiarity with different database systems (e.g. SQL, NoSQL, graph, timeseries)
- Expertise with sensitive data in critical environments (healthcare, defense, etc.)
- Expertise within most of the following areas: supervised learning, unsupervised learning, deep learning, LLMs, reinforcement learning, federated learning, time series forecasting, Bayesian statistics, optimization
- Comfortable working in cloud and high-performance computing environments (e.g. AWS, GCP, Databricks, Apache Spark)
- Hands-on AI/ML modeling experience of complex datasets combined with strong understanding of theoretical foundations of AI/ML (CI/CD, Orchestration)
- Experience in data visualisation technologies and libraries of Tableau, Power BI, Streamlit, Plotly, seaborn or similar
- Experience with various enterprise-level Application Programming Interfaces (APIs)
- Good knowledge of AI regulations
- PhD in mathematics, computer science, engineering, physics, statistics, economics, or a related quantitative discipline with strong coding skills, OR Master’s Degree in relevant domain
- English, French
- Work with business teams to understand requirements, and translate them into technical needs
- Apply data science expertise in machine/deep learning, statistics, forecasting and optimization to multiple AI projects/products
- Gather/organize large & complex data assets, and perform relevant analysis to propose and implement relevant data models for each business case
- Build models, algorithms, simulations, and experiments by writing highly optimized code and using state-of-the art machine learning technologies
- Work on full-spectrum of activities, from conducting ML experiments to delivering production-ready models
- Use data analysis, visualization, storytelling, and data technologies to scope, define and deliver AI-based data products
- Work with developers, engineers, and MLOps to industrialize and deliver scalable AI/ML solutions
- Participate and contribute to the global data science community of practice
- Be accountable and responsible for the robustness of the AI solution
- Apply responsible AI framework and governance best practices such as monitoring, explainability, trustworthy, ethical
- Mentor junior data scientists and analysts providing guidance in career development and technical growth
- Experience in a healthcare company is a strong plus
- Experience in IoT and timeseries forecasting is a plus
Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi reported a 20% profit growth in Q1 2025, driven by Dupixent and new launches.
- The FDA approved Dupixent for chronic spontaneous urticaria, expanding its treatment indications.
- Sanofi's investment in Innate Pharma supports its strategic goals in oncology.
What critics are saying
- Increased competition in immunology could impact Dupixent's market share.
- Potential delays in EU approval for tolebrutinib may affect market entry.
- The Dren Bio acquisition may not yield expected financial returns.
What makes Sanofi unique
- Sanofi's Dupixent is the first targeted therapy for chronic spontaneous urticaria.
- Tolebrutinib is a potential first-in-class therapy for non-relapsing secondary progressive multiple sclerosis.
- Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability